Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MYELOMATCH Clinical Trials
Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies (LUMOS2)
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
NEoadjuvant chemoradiotherapy for Esophageal scc vs Definitive chemoradiotherapy with salvage Surgery as needed (NEEDS Trial)
Dr. Michael McKenzie is a radiation oncologist with extensive experience in genitourinary oncology, neurooncology and palliative oncology at the BC Cancer Agency (BCCA), Vancouver Cancer Centre, and a Clinical Professor in the Division of Radiation Oncology and Developmental Radiotherapeutics at University of British Columbia. He works with patients with genitourinary cancers and brain tumours. He has served as Chair of BCCA’s Palliative Care Network.
It is with great sadness that CCTG shares the news of the passing of Aldo Del Col, a valued member of the CCTG Patient Representative Committee and the Hematology Disease Site Committee. He worked tirelessly to ensure that the patient voice was part of the design and conduct of CCTG clinical trials.
The Award
In recognition of the critical role played by the CCTG throughout her professional career, Dr. Shepherd is giving back by sharing her Gairdner Award with the CCTG. This award, to be endowed in perpetuity, will recognize excellence in clinical trials and translational research and will be open to all qualified CCTG investigators and post graduate trainees working on CCTG research projects.Each award will be $1000 and offered twice a year.
Eligibility
The Pharmacist Network is actively seeking a volunteer as Pharmacist Representative for the Lung Disease Site Committee.
The Pharmacist Disease Site Committee representative is expected to represent the perspective of the Pharmacist community during discussion of potential new studies and ongoing trials. Please review terms of reference at: Pharmacist Representatives on Disease Site Committees
Three new publications from the CCTG Committee on Economic Analysis
CCTG would like to welcome our new Senior Investigator, Dr. James Taylor.
iRECIST training has been a recommended component of immuno-oncology (IO) protocol training documentation in the CCTG Site Training Utility (STU) since 2017. We have recently updated the iRECIST training slides in STU and as of Thursday July 18, 2019, documentation of iRECIST training is now mandatory for Qualified Investigators (QI) participating on new IO trials. In addition to new studies, some recently opened/actively accruing/planned studies will also require documentation of this training for the QI. These trials are: HN9, I227, I238 and I239 (planned).
BRC7 trial has been centrally activated, this is a Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Post Progression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker Signature-driven Analysis
Activation Date: July 10, 2019 NCT Registration ID: NCT03793179
